Biomarkers for the clinical evaluation of cognitive impairment

Biomarkers for the clinical evaluation of the cognitively impaired elderly, amyloid is not enough

Recently published in the journal Imaging in Medicine (June, 2012), Linda K. McEvoy and James B. Brewer argue that while incorporating biomarkers for assessing Alzheimer’s disease risk, including volumetric MRI done with NeuroQuant®, can help in patient prognosis, tests for amyloid, if used in isolation, have potential for harm, as amyloid tests are clinically useful only when evidence suggests progressive cognitive decline or neurodegeneration. (Imaging in Medicine, June 2012, Vol. 4, No. 3 , Pages 343-357).

[button]Download[/button]

Insights

01/09/2025

Cortechs.ai Announces Oversubscribed Funding Round to Accelerate Innovation in AI-Powered Neuroimaging and Oncology Solutions

This investment propels our mission to revolutionize medical imaging in neuroimaging and oncology, enhancing diagnostic confidence and patient outcomes.

01/09/2025

Cortechs.ai Partners with Mermaid Beach Radiology to Bring Precision AI Imaging Solutions to Their MRI and CT Services

This collaboration marks a leap forward in delivering innovative, data-driven care and reflects our excitement to expand our reach globally.

12/19/2024

Elevating Neurological CT Precision and Efficiency

Learn how this powerful tool improves measurement accuracy, clinical confidence, and patient outcomes by streamlining workflows.
Scroll to Top